Sandoz Group AG Stock
Price
Target price
€61.66
€61.66
-2.740%
-1.74
-2.740%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Sandoz Group
sharewise wants to provide you with the best news and tools for Sandoz Group, so we directly link to the best financial data sources.
Financials
News
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options